GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma. Levels decline from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This age-related decline is linked to reduced wound healing, skin regeneration, and systemic tissue repair capacity, making it a subject of anti-aging research.

GHK-Cu modulates the expression of over 4,000 human genes, including those governing collagen and elastin synthesis, glycosaminoglycan production, stem cell recruitment, and antioxidant enzyme expression. It activates the FAK-paxillin signaling pathway to stimulate cell migration and tissue remodeling, and suppresses pro-inflammatory and pro-fibrotic pathways such as TGF-beta overactivation.

GHK-Cu is legal as a cosmetic ingredient in topical formulations and is sold without restriction in most countries. When used injectably for research purposes, it falls under the research chemical category and is not an FDA-approved drug. No prescription is required for topical use. Injectable forms exist in a legal gray area similar to other research peptides.

Topical formulations typically use 1 to 3 percent GHK-Cu applied twice daily to the face or target area. Injectable research protocols typically use 1 to 2 mg subcutaneously per day in 4 to 6 week cycles. Injectable use is not FDA-approved and is based on extrapolation from preclinical wound-healing studies, not clinical trials in healthy adults.

GHK-Cu is generally well tolerated. The most commonly reported side effects from injectable use are injection site irritation and mild redness. Topical use may occasionally cause skin redness and mild stinging, particularly at higher concentrations or on sensitive skin. Serious adverse events have not been reported in the published literature, though large-scale human safety trials are lacking.

Yes. Preclinical studies show GHK-Cu stimulates collagen synthesis in human dermal fibroblasts at concentrations as low as 1 nM, producing increases of approximately 70 percent compared to controls. Animal wound healing studies have shown efficacy comparable to retinoic acid. GHK-Cu also increases elastin and glycosaminoglycan synthesis, supporting broader dermal matrix restoration.

GHK-Cu has a plasma half-life of approximately 1 hour following subcutaneous injection. This short half-life reflects rapid tissue uptake and copper delivery to sites of repair. Topical formulations provide slower, more sustained local delivery without the pharmacokinetic considerations of injectable routes.